The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares